|View printer-friendly version|
|Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18|
“Factor Xa inhibitor-related bleeding leading to hospital admission and death is increasing because the adoption of these agents is growing significantly, and there is currently no approved reversal agent for patients,” said
Portola is developing andexanet alfa as a universal antidote for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled or life-threatening bleeding event or who require urgent or emergency surgery. Andexanet alfa is currently under review by the
ACC also has accepted two poster presentations regarding the unmet medical need for anticoagulant prophylaxis of venous thromboembolism in acute medically ill patients.
Poster Presentation Details:
About Portola Pharmaceuticals, Inc.
This announcement contains forward-looking statements, including statements relating to Portola Pharmaceuticals’ expectations regarding the anticipated regulatory review timeline for andexanet alfa. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected.